What is Claimed:

1. Use of an extracellular vesicle (EV) comprising an exogenous NLRP3 antagonist in the manufacture of a medicament for the treatment of peripheral neuropathy, or one or more symptoms of a peripheral neuropathy, in a subject in need thereof.

2. The use of claim 1, wherein the exogenous NLRP3 antagonist is a chemical compound, an siRNA, an shRNA, an antisense oligonucleotide, a protein, or any combination thereof.


3. The use of claim 1 or 2, wherein the EV targets a cell selected from the group consisting of a macrophage, a myeloid-derived suppressor cell (MDSC), a monocyte, a basophil, a neutrophil, an eosinophil, and any combination thereof.

4. The use of any one of claims 1 to 3, wherein the EV comprising the ASO or the ASO induces M2 macrophage polarization in the subject.

5. The use of any one of claims 1 to 4, wherein the EV comprising the ASO or the ASO reduces myeloid inflammation in a nerve, meningeal myeloid inflammation, nerve sheath inflammation, or any combination thereof, and/or reduces macrophage influx and/or phagocytosis in one or more of a root, nerve, and/or muscle.

6. The use of any one of claims 1 to 5, wherein the exogenous NLRP3 antagonist is a small molecule selected from the group consisting of MCC950, Tanilast, Oridonin, CY-09, Bay 11-7082, Parthenolide, 3,4-methylenedioxy-β-nitrostyrene (MNB), β-hydroxybutyrate (BHB), dimethyl sulfoxide (DMSO), type I interferon, and any combination thereof.

7. The use of claim 6, wherein the exogenous NLRP3 antagonist comprises the formula (I):



(I).

8. The use of any one of claims 1 to 7, wherein the exogenous NLRP3 antagonist comprises (i) MCC950; (ii) an antisense oligonucleotide (ASO); or (iii) both, wherein the ASO is a gapmer, a mixmer, or a totalmer and/or comprises one or more 5'-methyl-cytosine nucleobases.

9. The use of claim 8, wherein the ASO comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within a *NLRP3* transcript, wherein the contiguous nucleotide sequence comprises one or more modified internucleoside linkages and is at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% complementary to the nucleic acid sequence within the *NLRP3* transcript and is complementary to a nucleic acid sequence within (i) a 5' untranslated region (UTR); (ii) a coding region; or (iii) a 3' UTR of the *NLRP3* transcript.

10. The use of claim 8 or 9, wherein the ASO is capable of reducing NLRP3 protein and/ or mRNA expression in a human cell (*e.g.*, an immune cell), wherein the human cell expresses the NLRP3 protein and/or mRNA.

11. The use of any one of claims 8 to 10, wherein the ASO comprises one or more nucleoside analogs, wherein one or more of the nucleoside analogs (i) comprises a 2'-O-alkyl-RNA; 2'-O-methyl RNA (2'-OMe); 2'-alkoxy-RNA; 2'-O-methoxyethyl-RNA (2'-MOE); 2'-amino-DNA; 2'-fluro-RNA; 2'-fluoro-DNA; arabino nucleic acid (ANA); 2'-fluoro-ANA; or bicyclic nucleoside analog; (ii) is a sugar modified nucleoside, wherein the sugar modified nucleoside is an affinity enhancing 2' sugar modified nucleoside; (iii) comprises a nucleoside comprising a bicyclic sugar; (iv) comprises an LNA; or (v) comprises any combination of (i) to (iv).

12. The use of any one of claims 8 to 11, wherein the ASO comprises a nucleotide sequence selected from SEQ ID NOs: 101-200, with one or two mismatches.

13. The use of any one of claims 1 to 12, wherein the EV comprises an anchoring moiety, wherein the NLRP3 antagonist is linked to the anchoring moiety.

14. The use of any one of claims 1 to 13, wherein the EV comprises an exogenous targeting moiety, wherein the exogenous targeting moiety comprises a peptide, an antibody or an antigen-binding fragment thereof, a chemical compound, an RNA aptamer, or any combination thereof.

15. The use of claim 14, wherein the EV comprises a scaffold moiety linking the exogenous targeting moiety to the EV.

16. The use of any one of claims 13 to 15, wherein the exogenous NLRP3 antagonist is linked to the anchoring moiety and/or the scaffold moiety on the exterior or luminal surface of the EV by a linker.

17. The use of claim 16, wherein the linker is a polypeptide or non-polypeptide moeity.

18. The use of any one of claims 1 to 17, wherein the EV is an exosome.

19. The use of any one of claims 1 to 18, wherein the peripheral neuropathy is associated with diabetes, a trauma, an autoimmune disorder, a kidney disorder, a liver disorder, hypothyroidism, a vascular disorder, an abnormal vitamin level, alcohol use, or any combination thereof or wherein the peripheral neuropathy comprises chemotherapy-induced peripheral neuropathy (CIPN).

20. The use of any one of claims 1 to 19, wherein the EV reduces the severity or occurrence of one or more symptom in the subject selected from tingling, pain, burning, numbness, sensitivity to hot, sensitivity to cold, difficulty with fine motor skills, and any combination thereof.